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Carl Keen: one of the things that was stressed in the latest IoM1 biomarker report is the 
suggestion that all of the food claims today should be at about the same level of a standard 
pharmaceutical. Miguel, you touched upon this. The cost of that may be prohibitive. Is 
it reasonable to ask that of the food industry or do we have to find some way to tweak 
it? Is there a light at the end of the tunnel?
Barbara Schneeman: fDa’s goal with the biomarker report had been to identify a bet-
ter process to develop validated biomarkers. for diseases for which we don’t have valid 
biomarkers—many of the cancers for example—the only clinical studies that are possible 
to ascertain decreased risk are long term. with suitable biomarkers that are surrogate 
endpoints of disease, shorter-term studies are possible. So the recommendations were a 
little bit confusing based on what fDa had hoped to get out of that report, but we are 
gleaning, we are looking through it and hoping that the scientific community may be able 
to identify ways that they can take biomarkers that are currently in use and validate them 
as surrogate endpoints or develop new biomarkers that might be used in that capacity.
Roger Wasson (Wasson and Associates): You’ve talked about the regulations and about the 
rating systems and the labels, but I wondered if you would each go outside your own 
area and comment about advertising, because even some of the groups that you have 
regulated are able to come together and say something about “heart healthy” or omega-3 
or something else, on the web, in advertising and public relations—technically discon-
nected from the label itself—and advance a conversation on some of these issues that are 
quasi-claim making, but are not necessarily clearly regulated.
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Joanne Lupton: actually, I think it’s the opposite right now. I’m actually surprised how the 
federal trade Commission, the ftC, is coming after people for advertising and websites. 
If it’s on the label and it’s on the website, it counts the same, and fDa can go after those 
individuals. That’s coming under more scrutiny rather than less.
Schneeman: as Joanne mentioned, we have a guidance document on our website pointing 
out when material on the web can be considered labeling. for example, if a website UrL 
is provided on a food label then we can review anything on that website as labeling. The 
most famous instance in the United States was the cherry juice case about cancer. we can 
also look at advertising as a way of understanding the manufacturer’s intended use of the 
product. So, it’s not that we are regulating the advertising, but if it gives us information 
in a situation in which we might need to take enforcement action, we can use it to help 
inform our process. as a segue from your question, ftC was instructed by Congress to 
convene a work group from CDC, fDa and USDa to develop a report on criteria for 
marketing foods to children and, in December of 009, a workshop was held in wash-
ington, DC, with a preliminary discussion of the criteria that the work group had been 
considering. ftC will publish a Federal Register notice with the proposed criteria, with 
the goal of receiving comment before it actually sends its report to Congress, which is 
due in July 00. I know that this has been an area of interest in europe as well. Children 
are a vulnerable group. Should we be taking more steps to manage what is marketed and 
promoted to children in terms of food choice?
Miguel da Silva: and, in the case of europe, the claims regulation applies to all com-
mercial communications, including websites and advertising, as I said. for example, 
last year, I think it was the aSa, the advertising Standards authority, of the United 
Kingdom prohibited ads on television for some food companies because they were not 
complying with the claims regulation. So, that is already having an effect on advertising 
per se in the UK.
Rickey Yada (University of Guelph): we often talk about science-based policy. Should we 
be looking at policy-based science now?
Lupton: actually there is definitely a role for both and what you heard from the panel 
here is how we use scientific evidence to support the development of a policy, specifically 
around claims. But, where we probably need the research to go in the other direction, 
keep in mind that the intent with nutrition labeling is to help consumers make better 
food choices, and research can be done to help us figure out whether we are achieving that 
goal. are there ways that we should be improving our labeling? Certainly in the front-of-
pack labeling arena, there is a lot of speculation that this is going to be a tool that helps 
consumers, particularly some consumer groups that aren’t currently using nutrition facts. 
research can help us understand behavior, so, as the policy evolves, you need research to 
understand the impact the policy is having.
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da Silva: In europe, we have clearer separation between the risk assessors and the risk 
managers. That’s why, in my presentation, I explained that the european food Safety 
authority looks at the science, but it’s really the Commission and the Member States that 
authorize or decline the claim. now, they tend to follow efSa advice, so if efSa says that 
the claim is scientifically justified then the Commission and regulators will approve it. 
However, what we are seeing also is, in the case of nutrient profiles, efSa gave an opinion 
on how profiles could be established, but now it’s pure politics. no science is involved.
Amanda Martin (University of Minnesota): even if you ban claims, you’re not banning 
the food. will it actually affect consumer choice? By taking away the “probiotic” claim 
will yogurt consumption rates go down?
da Silva: Yes, that is a problem. for a functional food, if they cannot make a claim, who 
will pay more to buy it? and that’s particularly the case for antioxidants, for probiotics 
and for all food supplements. If you have a pill, but the label doesn’t tell you what it does 
for you, then why would you buy it? So, it really has a serious impact. of course, even if 
a claim is prohibited, your product can remain on the market, but, if you have developed 
it as a functional food delivering a health benefit, you will want to communicate that to 
the consumer. when claims for probiotics were being rejected, Dannon withdrew their 
dossier on activia, so as not to have a public rejection on their dossier. They have stopped 
their claims, but are keeping the products on supermarket shelves because people, having 
been “educated,” are familiar with the media messages. However, I wonder what will be the 
situation in a number of years, because to educate people you need to educate constantly 
as the consumer population evolves.  
Schneeman: You raised an interesting point and it can play out in different ways. first of all, 
yogurt can be part of a healthful diet. If you are interested in consuming dairy products, 
that is certainly one way to do it. It’s not surprising that consumers tend to think positive 
of a product like that. a company that chooses to go down that path has to weigh the risks 
to them. Because, on the one hand, they do gain a halo if it looks like their product has 
a health benefit. But then, having a negative message come out about that product could 
tarnish that halo. If consumers already believe it and let’s say it’s a placebo effect, then the 
tarnish may not impact them, but, in some cases, it can have a much more negative effect: 
why would I trust a company that has said something not supported by the science? It 
gets complicated in terms of the messaging and how consumers perceive it.
